



# Furocyst<sup>®</sup>

For Management of PCOS

**CLINICALLY EVALUATED &  
PATENTED INGREDIENT**

## INTRODUCTION

Polycystic ovarian syndrome (PCOS) is one of the most common endocrine disorders. In young girls, the symptoms are mainly cosmetic as they get disturbed by acne, weight gain and facial hair. In married women, PCOS often manifests as inability to conceive. PCOS affects an estimated 1 in 10 women, which is why National Institute of Health (NIH) has announced it as a major public-health issue for women.

PCOS is of clinical and public health importance as its prevalence is very high among women of reproductive age.

## WOMEN'S HEALTH

Furocyst® is a patented product derived from single herb with a proprietary manufacturing process involving separation of active ingredients without affecting chemical properties of the active fractions.

Furocyst is supported by 5 international patents & 3 clinical studies on a total of 520 subjects for management of PCOS and the same have been published in well-known international journals like WJPR, IJMS, FASEBJ and NCBI. It has been proven safe and effective. Furocyst has also been accepted under the Prime Minister's Fellowship Scheme for Doctoral Research.

Furocyst is touted to improve insulin sensitivity and, in turn, may regulate circulating androgen levels. It is also said to improve insulin-mediated glucose disposal in women with PCOS. Furocyst helped to improve menstrual period in the study subjects and thus, might be regulating effect of insulin on ovarian androgen biosynthesis, theca cell proliferation and endometrial growth. It might be regulating ovarian androgen production leading to disappearance or decrease in size and number of cysts.

# CLINICAL EVALUATION OF FUROCYST

## STUDY 1

(Carried out on 370 patients)

### EFFICACY CONCLUSION

- 80% of the patients showed decrease in number of cysts in right ovary and 70.59% of the patients showed decrease in number of cysts in left ovary.
- 83.33% of the patients showed decrease in right ovary volume and 73.26 % of the patients showed decrease in number of cysts in left ovary.
- 67.68% of study population showed improvement in Hirsutism score.
- Total 34 Females got pregnant, 30 during the study and 4 after the completion of treatment.
- 91.25% of the study population showed improvement in menstrual cycle.

## STUDY 2

(Carried out on 107 patients)

### EFFICACY CONCLUSION

- The left ovary volume was decreased in 90% of the patients and right ovary volume was decreased in 96.7% of subjects.
- 41.57% of the patients showed decrease in right ovary volume and 44.92% of the patients showed decrease in number of cysts in left ovary
- 8 patients got pregnant during study.
- HOMA index was also shown to be significantly reduced up to 46.54% in 75.67% of the study population till the completion of the treatment.
- 79.5% of the study population had regular menstrual cycle.
- Mean Prolactin levels were significantly decreased on completion of treatment.

## STUDY 3

(Carried out on 50 patients)

### EFFICACY CONCLUSION

- 46% of the study population showed a reduction in cyst size.
- 36% of the study population showed complete dissolution of the cysts.
- 12% of the patients got pregnant.
- 71% of the patients reported regular menstrual cycle on completion of the treatment.
- Overall 94% of the patients reported positively or got benefitted from the fenugreek extract dosing.

### SAFETY CONCLUSION

There was no significant change in Liver Function Test, Renal Function Test, Hemogram and Lipid Profile.

### SALIENT FEATURES OF FUROCYST

- ♀ Research-based innovative ingredient
- ♀ Protected by product and process patents
- ♀ Stability studies established
- ♀ 100% water soluble ingredient

**For any enquiries, please write us at:**

**Email:** corporate@chereso.net



**For US – Email:** kelly@cepham.com

